Abstract
The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-α based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.
Keywords: Hepatitis C, insulin resistance, interferon-α, vascular disease, oxidative stress, Interferon (INF), interferon-receptor, Jak/STAT, ISGF3, HOMA-IR, SOCS3, protein phosphatase 2A, PIAS1, protein arginine methyl-transferase (PRMT1), B kinase-beta (IKK), Etanercept, TNF-protein, T1DM, T2DM, HEPATIC STEATOSIS (HS), metabolic steatosis, non alcoholic fatty liver disease, Thiazolidinediones, pioglitazone, rosiglitazone, peroxisome proliferator activated receptors, PPAR- mRNA, STATIN THERAPY AND CHC
Current Pharmaceutical Design
Title: Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Volume: 16 Issue: 34
Author(s): Andreja Trpkovic, Edith Stokic, Djordje Radak, Zoran Gluvic, Mohamed Haidara, Dimitri P. Mikhailidis and Esma R. Isenovic
Affiliation:
Keywords: Hepatitis C, insulin resistance, interferon-α, vascular disease, oxidative stress, Interferon (INF), interferon-receptor, Jak/STAT, ISGF3, HOMA-IR, SOCS3, protein phosphatase 2A, PIAS1, protein arginine methyl-transferase (PRMT1), B kinase-beta (IKK), Etanercept, TNF-protein, T1DM, T2DM, HEPATIC STEATOSIS (HS), metabolic steatosis, non alcoholic fatty liver disease, Thiazolidinediones, pioglitazone, rosiglitazone, peroxisome proliferator activated receptors, PPAR- mRNA, STATIN THERAPY AND CHC
Abstract: The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-α based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.
Export Options
About this article
Cite this article as:
Trpkovic Andreja, Stokic Edith, Radak Djordje, Gluvic Zoran, Haidara Mohamed, P. Mikhailidis Dimitri and R. Isenovic Esma, Chronic Hepatitis C, Insulin Resistance and Vascular Disease, Current Pharmaceutical Design 2010; 16 (34) . https://dx.doi.org/10.2174/138161210794455067
DOI https://dx.doi.org/10.2174/138161210794455067 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
QSAR Studies on some Calcium Channel Blockers
Letters in Drug Design & Discovery The Intermediate-Conductance Ca2+-Activated K+ Channel (KCa3.1) in Vascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design Current Concepts on Prenatal Diagnosis and Management of Fetal Tachyarrythmias
Current Cardiology Reviews Arecoline Increases the Production of Nitric Oxide and Post-Translational S-Nitrosoproteome in Endothelial Cells
Current Proteomics Role of the Sex Hormone Estrogen in the Prevention of Lipid Disorder
Current Medicinal Chemistry Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications
Cardiovascular & Hematological Disorders-Drug Targets Genetic Variations and Subclinical Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus
Current Vascular Pharmacology Exercise Limitation in Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews The Metabolic Syndrome and Chronic Liver Disease
Current Pharmaceutical Design MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis
Current Vascular Pharmacology Evaluation of Risk Factors Associated with Diabetic Foot Ulcers in Saudi Arabia
Current Diabetes Reviews Effects of Music Therapy on Psychological Symptoms and Heart Rate Variability in Patients with Dementia. A Pilot Study
Current Aging Science Menopause and its Cardiometabolic Consequences: Current Perspectives
Current Vascular Pharmacology Editorial (Thematic Issue: Idiopathic Pulmonary Fibrosis)
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Ischemic and Oxidative Damage to the Hypothalamus May Be Responsible for Heat Stroke
Current Neuropharmacology Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design From Gene to Epigene-Based Therapies Targeting the Vascular Endothelium
Current Vascular Pharmacology